Expanding Portfolio
Oculis SA has agreed to license a topical anti-TNF alpha antibody from Novartis
Colin Kerr
Published: Friday, February 1, 2019
Oculis SA has entered into an agreement to license a novel topical anti-TNF alpha antibody from Novartis.
The compound, LME 636, is based on a proprietary single-chain antibody fragment technology specifically designed for topical delivery. Efficacy and safety were evaluated in three clinical trials.
Dr Riad Sherif, Oculis CEO, said: “This agreement is part of our ongoing strategy to access multiple sources of technologies and compounds that bolster our portfolio of innovative products to treat eye diseases.”
www.oculis.com
Tags: anti-TNF alpha antibody, ophthalmic disease
Latest Articles
Simulators Benefit Surgeons and Patients
Helping young surgeons build confidence and expertise.
How Many Surgeries Equal Surgical Proficiency?
Internet, labs, simulators, and assisting surgery all contribute.
Improving Clinical Management for nAMD and DME
Global survey data identify barriers and opportunities.
Are Postoperative Topical Antibiotic Drops Still Needed?
Cataract surgeons debate the benefits of intracameral cefuroxime prophylaxis.
Emerging Technology for Detecting Subclinical Keratoconus
Brillouin microscopy shows promise in clinical studies.
Knowing Iris Repair: Modified Trifold Technique
Part eight of our series covers the modified trifold technique for large iris defects.
It’s All About Biomechanics!
Increasing the pool of patients eligible for refractive surgery.
Uncovering More Safe and Quick Options
Different strategies, such as PresbyLASIK, can offer presbyopes good outcomes.
Topography-Guided PRK for Keratoconus
Improving visual acuity in patients with keratoconus.
Defining AMD Treatment Protocol
Treatments trending to fewer injections for better results.